The shadow of generic rivalry has consistently loomed around copyright’s famous drug, PDE5 Inhibitor, raising questions about the future of related drug investments. While first years saw significant returns, the exclusivity lapse has opened the path for less expensive copies, likely reducing revenue and posing a real hazard for investors pursuin